INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $5,509,000 | -49.2% | 87,500 | +0.0% | 0.20% | -28.6% |
| Q4 2019 | $10,839,000 | -2.7% | 87,468 | -47.9% | 0.28% | -8.9% |
| Q3 2019 | $11,142,000 | +8.3% | 167,902 | +29.8% | 0.30% | +19.3% |
| Q2 2019 | $10,292,000 | -17.9% | 129,346 | +15.4% | 0.25% | -19.1% |
| Q1 2019 | $12,538,000 | +15.7% | 112,087 | +4.2% | 0.31% | +2.6% |
| Q4 2018 | $10,840,000 | -14.2% | 107,553 | +7.6% | 0.31% | +2.3% |
| Q3 2018 | $12,628,000 | -0.6% | 99,938 | -34.0% | 0.30% | -5.7% |
| Q2 2018 | $12,707,000 | +79.2% | 151,434 | +31.4% | 0.32% | +83.2% |
| Q1 2018 | $7,090,000 | +0.5% | 115,245 | -4.6% | 0.17% | +4.2% |
| Q4 2017 | $7,055,000 | – | 120,757 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |